Development of Corona Virus vaccine In Japan, the country subsidizes the remainder of the yen May 22 at 15:17
In order to promote the development of vaccines for the new coronavirus, it has been decided that the government will subsidize more than 7 billion yen in nine studies in Japan. Of these, there are expectations for early development, as clinical trials are expected to begin in July.
Regarding the development of vaccines for the new coronavirus, the Ministry of Health, Labour and Welfare set aside 10 billion yen in the supplementary budget for this fiscal year to support from basic research to a part of clinical trials.
For research to be supported, the Japan Medical Research and Development Organization has made a public offering, and has adopted a new number of companies-led projects and university-led projects.
Companies such as pharmaceutical companies have led companies in Tokyo Chiyoda-ku, Tokyo, Andy Pharmaceutical co., Ltd., Osaka City’s ShionoYoshi Pharmaceutical Co., Ltd., Kumamoto City’s “Biologics”, and “Angers” in Ibaraki City, Osaka.
Led by universities and other initiatives, keio university has 258 million yen, the University of Tokyo has 200 million yen, Nagasaki University has 50 million yen, Niigata University has 38 million yen, and the Tokyo Metropolitan Institute of Medical Sciences has 500 million yen.
According to the Japan Medical Research and Development Organization, a total of 7.2 billion yen will be subsidized for the nine studies, including other expenses.
Of the 10 billion yen recorded in the supplementary budget, the remaining 2.8 billion yen has not yet been spent.
According to the Ministry of Health, Labour and Welfare, the research that Angers is conducting in collaboration with Osaka University is expected to begin clinical trials in July, so there is high expectations for early development.